Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people wi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 2007-07, Vol.191 (1), p.14-22
Main Authors: Davies, Linda M., Lewis, Shôn, Jones, Peter B., Barnes, Thomas R. E., Gaughran, Fiona, Hayhurst, Karen, Markwick, Alison, Lloyd, Helen
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - economics
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Antipsychotics
Atypical
Cost analysis
Cost effectiveness
Cost-Benefit Analysis
Female
First generation
Health care expenditures
Health status
Humans
Male
Mental disorders
Patients
Pharmaceutical industry
Prescription drugs
Psychiatry
Psychosis
Psychotropic drugs
Quality of life
Quality-Adjusted Life Years
Randomized controlled trials
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - economics
Second generation
Sensitivity analysis
Statistics as Topic
Substance abuse treatment
United Kingdom
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice. Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective. The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.bp.106.028654